Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

VANCOUVER, and SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three months ended July 31, 2007 and an update on its programs.

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. This confirmatory Phase III trial is a randomized, Evaluation Committee-blinded study to assess the effectiveness of Omigard(TM) vs. 10% povidone-iodine for the prevention of central venous catheter-related infections. This ongoing trial is known as the Central Line Infection Reduction Study, or CLIRS trial.

On July 30, 2007 Cadence Pharmaceuticals, our North American and European development and commercialization partner for Omigard(TM), announced that the FDA had agreed with their plan to increase the number of patients to be enrolled in CLIRS trial from 1,250 to 1,850. Cadence also announced that in June 2007 it completed enrollment of the original target of 1,250 patients in this clinical trial. Cadence expects they will complete enrollment of the new goal of 1,850 patients in the second quarter of 2008. If the results of the CLIRS trial are positive, Cadence expects to submit an NDA for omiganan 1% gel in the first half of 2009.

Celgosivir (MX-3253; oral a-glucosidase I inhibitor; treatment of chronic hepatitis C virus infections): Final top-line results of a Phase II combination study in non-responder and partial responder patients were announced April 11, 2007, demonstrating proof-of-concept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegylated interferon plus ribavirin) as compared to the active control treatment (standard-of-care
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... May 16, 2013 In late 2012, Dr. ... speak to doctors in China about Appearance Medicine . ... this was her first trip to lecture in China, and ... Guangzhou and Fuzhou, home to 12 and 7 million people ... very high at this point in time. As Dr. Hart ...
(Date:5/16/2013)... Needham, Mass. (PRWEB) May 16, 2013 ... Bioprocessing Summit from August 19-23, 2013 at the Renaissance ... comprising the Summit provide a close-up look at the ... risk and ensuring bottom-line quality. Leaders in the ... innovative ways to produce biopharmaceuticals with greater specificity and ...
(Date:5/16/2013)... 2013  HealthSparq, a trusted provider of healthcare ... regional health plans, will debut a new benchmark ... Institute 2013 conference on June 13.  The presentation ... health insurance companies across the country are thinking ... demands for increased healthcare transparency. ...
(Date:5/16/2013)... 16, 2013 Scientists at the Center for ... , and the California -based biopharmaceutical ... novel therapy for reversing memory decline in mice with ... significant cognitive improvement in advanced stage AD mice. The ... reversing cognitive decline for advanced stage AD mice, and ...
Breaking Biology Technology:The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3
... , EATONTOWN, N.J., July 29 ... in the emerging field of biologic products for regenerative healing, ... the Company, the French regulatory agency, afssaps, rescinded its December ... of tissue products processed from donors procured by TB OsteoCentre ...
... , VAN BUREN TWP., Mich. , ... of Ricardo plc, the leading independent provider of technology, product ... and new energy industries, has announced that the company is ... low carbon engine technologies. With the environmental demand to reduce ...
... , , SAN DIEGO, ... NBIX ) today announced new six month safety and ... using its proprietary, orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor ... previously reported six month (Petal Study) and three month ...
Cached Biology Technology:Osteotech Resumes Shipments of Bulgarian Tissue 2Osteotech Resumes Shipments of Bulgarian Tissue 3Ricardo Launches Consortium to Evaluate Lubricant Challenges of Future Low Carbon Engine Technologies 2Ricardo Launches Consortium to Evaluate Lubricant Challenges of Future Low Carbon Engine Technologies 3Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis 2Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis 3Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis 4
(Date:5/16/2013)... MD FASEB MARC (Maximizing Access to Research ... for The Society for Developmental Biology (SDB) 72nd ... 2013. These awards are meant to promote the ... groups into the mainstream of the basic science ... scientists at the SDB 2013 Annual Meeting. , ...
(Date:5/16/2013)... involved in neurodegenerative disease also plays a critical role ... , In a study of the common fruit fly, ... clock responsible for sleeping and waking on a 24-hour ... fly,s sleep-wake cycle is disturbed, making waking up on ... The discovery is particularly interesting because mutations in the ...
(Date:5/16/2013)... The relationship between the heritable risk for ... clear. Schizophrenia is commonly associated with cognitive impairments ... that reduced IQ may be linked to the ... ability may precede the onset of schizophrenia symptoms. ... relatives of people diagnosed with schizophrenia. , In ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 2Genetic risk for schizophrenia is connected to reduced IQ 2
... cancer is known to occur typically in older men. Yet ... of diagnosis. Scientists assume that these cases might be the ... cancer might be a subtype which is characterized by a ... is likely that these include a number of what are ...
... production and a growing need to find cost-effective livestock feedstuff ... the use of glycerin in swine diets. This ... Mendoza, was published in the Journal of Animal Science and ... glycerin and achieve similar performance to a conventional corn:soybean diet. ...
... The National Cancer Institute estimates that more than ... and more than 36,000 died from the disease. ... oncogene is mutated in virtually all pancreatic cancers, scientists ... pathways in humans, which make it difficult to pinpoint ...
Cached Biology News:Uncovering the genetics of prostate cancer 2Uncovering the genetics of prostate cancer 3Uncovering the genetics of prostate cancer 4University of Illinois study confirms glycerin as a feasible feedstuff for swine 2Roundworm unlocks pancreatic cancer pathway 2
... Eastman Kodak Companys Molecular Imaging ... KODAK Image Station 4000 Digital Imaging ... camera technology for comprehensive fluorescence, luminescence, ... systems 4 million pixel CCD and ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
... for the extraction of unwanted detergent ... macromolecules, Applications: ,Reducing octyl glucoside concentration ... of pure β-adrenergic receptor and pure ... in 6 M urea/0.05 mM Tris ...
... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
Biology Products: